{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:40:35Z","timestamp":1789983635648,"version":"4.0.1"},"reference-count":103,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2017.00011","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T10:15:58Z","timestamp":1485771358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Molecular Imaging Markers to Track Huntington\u2019s Disease Pathology"],"prefix":"10.3389","volume":"8","author":[{"given":"Heather","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"De Micco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Niccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Politis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"The huntington\u2019s disease collaborative research group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"The Huntington Study Group","year":"1993","journal-title":"Cell"},{"issue":"9","key":"B2","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov Disord"},{"key":"B3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ng0893-387","article-title":"Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease","volume":"4","author":"Duyao","year":"1993","journal-title":"Nat Genet"},{"issue":"6","key":"B4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/archneur.63.6.883","article-title":"Preparing for preventive clinical trials: the Predict-HD study","volume":"63","author":"Paulsen","year":"2006","journal-title":"Arch Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington\u2019s disease decades before diagnosis: the Predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","article-title":"Biological and clinical changes in premanifest and early stage Huntington\u2019s disease in the TRACK-HD study: the 12-month longitudinal analysis","volume":"10","author":"Tabrizi","year":"2011","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1212\/01.wnl.0000204230.16619.d9","article-title":"The association of CAG repeat length with clinical progression in Huntington disease","volume":"66","author":"Rosenblatt","year":"2006","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/mds.24024","article-title":"Age, CAG repeat length, and clinical progression in Huntington\u2019s disease","volume":"27","author":"Rosenblatt","year":"2014","journal-title":"Mov Disord"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1037\/a0020937","article-title":"Neurocognitive signs in prodromal Huntington disease","volume":"25","author":"Stout","year":"2011","journal-title":"Neuropsychology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"issue":"2","key":"B15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","article-title":"CAG repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches","volume":"153B","author":"Langbehn","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4329\/wjr.v6.i6.301","article-title":"Neuroimaging in Huntington\u2019s disease","volume":"6","author":"Niccolini","year":"2014","journal-title":"World J Radiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.brainresbull.2010.04.003","article-title":"Striatal and white matter predictors of estimated diagnosis for Huntington disease","volume":"82","author":"Paulsen","year":"2010","journal-title":"Brain Res Bull"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9226","DOI":"10.1073\/pnas.97.16.9226","article-title":"Positron emission tomography provides molecular imaging of biological processes","volume":"97","author":"Phelps","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1007\/s00415-015-7711-x","article-title":"Recent imaging advances in neurology","volume":"262","author":"Rocchi","year":"2015","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00415-012-6428-3","article-title":"Positron emission tomography imaging in neurological disorders","volume":"259","author":"Politis","year":"2012","journal-title":"J Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00259-016-3324-6","article-title":"Current status of PET imaging in Huntington\u2019s disease","volume":"43","author":"Pagano","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor regulated gene-expression of striatonigral and striatopallidal neurons","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/brain\/120.3.503","article-title":"PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington\u2019s disease","volume":"120","author":"Ginovart","year":"1997","journal-title":"Brain"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1212\/WNL.54.9.1753","article-title":"Decreased striatal monoaminergic terminals in Huntington disease","volume":"54","author":"Bohnen","year":"2000","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF02191583","article-title":"Dopamine D1 receptor number \u2013 a sensitive PET marker for early brain degeneration in Huntington\u2019s disease","volume":"243","author":"Sedvall","year":"1994","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","article-title":"Huntington\u2019s disease progression PET and clinical observations","volume":"122","author":"Andrews","year":"1999","journal-title":"Brain"},{"key":"B28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1212\/01.wnl.0000176071.08694.cc","article-title":"Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease","volume":"65","author":"van Oostrom","year":"2005","journal-title":"Neurology"},{"issue":"Pt 6","key":"B29","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/brain\/awg119","article-title":"Progressive striatal and cortical dopamine receptor dysfunction in Huntington\u2019s disease: a PET study","volume":"126","author":"Pavese","year":"2003","journal-title":"Brain"},{"issue":"Pt 3","key":"B31","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/brain\/118.3.689","article-title":"Striatal D1 and D2 receptor binding in patients with Huntington\u2019s disease and other choreas. A PET study","volume":"118","author":"Turjanski","year":"1995","journal-title":"Brain"},{"key":"B32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ana.410430216","article-title":"[11C]raclopride-PET studies of the Huntington\u2019s disease rate of progression: relevance of the trinucleotide repeat length","volume":"43","author":"Antonini","year":"1998","journal-title":"Ann Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/brain\/121.7.1343","article-title":"The relationship between striatal dopamine receptor binding and cognitive performance in Huntington\u2019s disease","volume":"121","author":"Lawrence","year":"1998","journal-title":"Brain"},{"issue":"Pt 12","key":"B34","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1093\/brain\/120.12.2207","article-title":"Cognitive deficits in Huntington\u2019s disease are predicted by dopaminergic PET markers and brain volumes","volume":"120","author":"B\u00e4ckman","year":"1997","journal-title":"Brain"},{"key":"B35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.nbd.2009.10.015","article-title":"Cortical dopamine dysfunction in symptomatic and premanifest Huntington\u2019s disease gene carriers","volume":"37","author":"Pavese","year":"2010","journal-title":"Neurobiol Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1093\/brain\/awn244","article-title":"Hypothalamic involvement in Huntington\u2019s disease: an in vivo PET study","volume":"131","author":"Politis","year":"2008","journal-title":"Brain"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/hbm.21134","article-title":"Extrastriatal dopamine D(2) receptor binding in Huntington\u2019s disease","volume":"32","author":"Esmaeilzadeh","year":"2011","journal-title":"Hum Brain Mapp"},{"key":"B38","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM198702123160701","article-title":"Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington\u2019s disease","volume":"316","author":"Mazziotta","year":"1987","journal-title":"N Engl J Med"},{"issue":"Pt 5","key":"B39","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/brain\/113.5.1405","article-title":"Cortical and subcortical glucose consumption measured by PET in patients with Huntington\u2019s disease","volume":"113","author":"Kuwert","year":"1990","journal-title":"Brain"},{"key":"B40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ana.410200305","article-title":"PET scan investigations of Huntington\u2019s disease: cerebral metabolic correlates of neurological features and functional decline","volume":"20","author":"Young","year":"1986","journal-title":"Ann Neurol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ana.410230603","article-title":"Positron emission tomographic scan investigations of Huntington\u2019s disease: cerebral metabolic correlates of cognitive function","volume":"23","author":"Berent","year":"1988","journal-title":"Ann Neurol"},{"issue":"Pt 9","key":"B42","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/brain\/120.9.1553","article-title":"Central motor processing in Huntington\u2019s disease. A PET study","volume":"120","author":"Bartenstein","year":"1997","journal-title":"Brain"},{"issue":"Pt 9","key":"B43","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/brain\/120.9.1569","article-title":"Cortical control of movement in Huntington\u2019s disease. A PET activation study","volume":"120","author":"Weeks","year":"1997","journal-title":"Brain"},{"key":"B44","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/00004647-199709000-00003","article-title":"11C-diprenorphine binding in Huntington\u2019s disease: a comparison of region of interest analysis with statistical parametric mapping","volume":"17","author":"Weeks","year":"1997","journal-title":"J Cereb Blood Flow Metab"},{"key":"B45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bandl.2009.05.004","article-title":"A PET study of word generation in Huntington\u2019s disease: effects of lexical competition and verb\/noun category","volume":"110","author":"Lepron","year":"2009","journal-title":"Brain Lang"},{"key":"B46","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1212\/WNL.36.7.888","article-title":"Positron emission tomography in the early diagnosis of Huntington\u2019s disease","volume":"36","author":"Hayden","year":"1986","journal-title":"Neurology"},{"key":"B47","first-page":"215","article-title":"Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington\u2019s disease","volume":"47","author":"Ciarmiello","year":"2006","journal-title":"J Nucl Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s00259-012-2114-z","article-title":"18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size","volume":"39","author":"Ciarmiello","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"B49","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00415-014-7350-7","article-title":"Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington\u2019s disease","volume":"261","author":"Herben-Dekker","year":"2014","journal-title":"J Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3988\/jcn.2013.9.1.21","article-title":"Decreased metabolism in the cerebral cortex in early-stage Huntington\u2019s disease: a possible biomarker of disease progression?","volume":"9","author":"Shin","year":"2013","journal-title":"J Clin Neurol"},{"key":"B51","first-page":"1591","article-title":"Metabolic network abnormalities in early Huntington\u2019s disease: an [(18)F]FDG PET study","volume":"42","author":"Feigin","year":"2001","journal-title":"J Nucl Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/brain\/awm217","article-title":"Thalamic metabolism and symptom onset in preclinical Huntington\u2019s disease","volume":"130","author":"Feigin","year":"2007","journal-title":"Brain"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1172\/JCI69411","article-title":"Metabolic network as a progression biomarker of premanifest Huntington\u2019s disease","volume":"123","author":"Tang","year":"2013","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","article-title":"Dopaminergic signaling and striatal neurodegeneration in Huntington\u2019s disease","volume":"27","author":"Tang","year":"2007","journal-title":"J Neurosci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fphar.2012.00096","article-title":"Imaging of microglia in patients with neurodegenerative disorders","volume":"3","author":"Politis","year":"2012","journal-title":"Front Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/glia.10144","article-title":"Visualising microglial activation in vivo","volume":"40","author":"Banati","year":"2002","journal-title":"Glia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.nurt.2007.04.006","article-title":"Positron emission tomography imaging of neuroinflammation","volume":"4","author":"Cagnin","year":"2007","journal-title":"Neurotherapeutics"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington\u2019s disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","article-title":"Microglial activation correlates with severity in Huntington disease: a clinical and PET study","volume":"66","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hbm.21008","article-title":"Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2019s disease: a multimodal imaging study","volume":"32","author":"Politis","year":"2011","journal-title":"Hum Brain Mapp"},{"key":"B61","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1006\/exnr.1999.7170","article-title":"Increased complement biosynthesis by microglia and complement activation on neurons in Huntington\u2019s disease","volume":"159","author":"Singhrao","year":"1999","journal-title":"Exp Neurol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","article-title":"Early and progressive accumulation of reactive microglia in the Huntington disease brain","volume":"60","author":"Sapp","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ng0595-104","article-title":"Cellular localization of the Huntington\u2019s disease protein and discrimination of the normal and mutated form","volume":"10","author":"Trottier","year":"1995","journal-title":"Nat Genet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nn.3668","article-title":"Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors","volume":"17","author":"Crotti","year":"2014","journal-title":"Nat Neurosci"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J Exp Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington\u2019s disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav Immun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","article-title":"Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington\u2019s disease gene carriers","volume":"83","author":"Politis","year":"2015","journal-title":"Neurobiol Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington\u2019s disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J Proteome Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/ng1542","article-title":"A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease","volume":"37","author":"Giorgini","year":"2005","journal-title":"Nat Genet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1083\/jcb.200508072","article-title":"Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity","volume":"171","author":"Shin","year":"2005","journal-title":"J Cell Biol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12149-015-0948-8","article-title":"Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [(11)C]CB184 and [(11)C]CB190, as a PET tracer for 18 kDa translocator protein: direct comparison with [(11)C](R)-PK11195","volume":"29","author":"Hatano","year":"2015","journal-title":"Ann Nucl Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0014-2999(91)90594-G","article-title":"Brain kinetics and specific binding of [11C]PK 11195 to omega 3 sites in baboons: positron emission tomography study","volume":"200","author":"Petit-Taboue","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J Biol Chem"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"B75","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1445-5994.1995.tb02886.x","article-title":"Second messenger pathways in the modulation of neurotransmitter release","volume":"25","author":"Majewski","year":"1995","journal-title":"Aust N Z J Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejphar.2013.06.038","article-title":"Phosphodiesterases: regulators of cyclic nucleotide signals and novel molecular target for movement disorders","volume":"714","author":"Sharma","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J Neurosci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1096\/fj.07-9814","article-title":"Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death","volume":"22","author":"Roze","year":"2008","journal-title":"FASEB J"},{"key":"B79","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/978-3-7091-0932-8_18","article-title":"Integrating neurotransmission in striatal medium spiny neurons","volume":"970","author":"Girault","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1212\/WNL.0000000000000037","article-title":"PET imaging shows loss of striatal PDE10A in patients with Huntington disease","volume":"82","author":"Ahmad","year":"2014","journal-title":"Neurology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The phosphodiesterase 10 positron emission tomography tracer, F-18 MNI-659, as a novel biomarker for early Huntington disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1212\/WNL.0000000000002391","article-title":"Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging","volume":"86","author":"Russell","year":"2016","journal-title":"Neurology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/brain\/awv214","article-title":"Altered PDE10A expression detectable early before symptomatic onset in Huntington\u2019s disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain"},{"key":"B84","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jns.2016.07.033","article-title":"Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington\u2019s disease gene carriers","volume":"368","author":"Wilson","year":"2016","journal-title":"J Neurol Sci Turk"},{"key":"B85","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ajhg.2016.03.015","article-title":"Biallelic mutations in PDE10A lead to loss of striatal PDE10A and a hyperkinetic movement disorder with onset in infancy","volume":"98","author":"Diggle","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B86","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ajhg.2016.02.015","article-title":"De novo mutations in PDE10A cause childhood-onset chorea with bilateral striatal lesions","volume":"98","author":"Mencacci","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"2","key":"B87","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","article-title":"Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain","volume":"77","author":"Glass","year":"1997","journal-title":"Neuroscience"},{"issue":"Pt 3","key":"B88","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1469-7793.2001.0731e.x","article-title":"Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons","volume":"532","author":"Huang","year":"2001","journal-title":"J Physiol"},{"issue":"2","key":"B89","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0306-4522(97)00597-6","article-title":"Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum","volume":"85","author":"Szabo","year":"1998","journal-title":"Neuroscience"},{"key":"B90","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0006-8993(01)03403-5","article-title":"Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington\u2019s disease","volume":"929","author":"Lastres-Becker","year":"2002","journal-title":"Brain Res"},{"issue":"5642","key":"B91","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.077156","article-title":"Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo","volume":"51","author":"Van Laere","year":"2010","journal-title":"J Nucl Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.neuroimage.2009.06.059","article-title":"Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand","volume":"48","author":"Terry","year":"2009","journal-title":"Neuroimage"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1053-8119(03)00241-6","article-title":"In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography","volume":"19","author":"Bauer","year":"2003","journal-title":"Neuroimage"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s00259-014-2724-8","article-title":"Cross sectional PET study of cerebral adenosine A(1) receptors in premanifest and manifest Huntington\u2019s disease","volume":"41","author":"Matusch","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B96","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/0006-8993(86)90946-7","article-title":"Opioid peptides in Huntington\u2019s disease: alterations in prodynorphin and proenkephalin system","volume":"378","author":"Seizinger","year":"1986","journal-title":"Brain Res"},{"issue":"1","key":"B97","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ana.410340114","article-title":"Positron emission tomography measures of benzodiazepine receptors in Huntington\u2019s disease","volume":"34","author":"Holthoff","year":"1993","journal-title":"Ann Neurol"},{"issue":"5","key":"B98","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/1531-8249(200005)47:5644::AID-ANA133.0.CO;2-C","article-title":"Benzodiazepine receptor binding in Huntington\u2019s disease: [11C]flumazenil uptake measured using positron emission tomography","volume":"47","author":"K\u00fcnig","year":"2000","journal-title":"Ann Neurol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"1\u20132","key":"B100","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0166-4328(96)00106-4","article-title":"Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders","volume":"73","author":"Wong","year":"1996","journal-title":"Behav Brain Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1046\/j.1471-4159.2002.01084.x","article-title":"Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington\u2019s disease","volume":"82","author":"Yohrling","year":"2002","journal-title":"J Neurochem"},{"key":"B102","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/ana.20075","article-title":"Paroxetine retards disease onset and progression in Huntingtin mutant mice","volume":"55","author":"Duan","year":"2004","journal-title":"Ann Neurol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1046\/j.1460-9568.1999.00453.x","article-title":"Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington\u2019s and Parkinson\u2019s disease cases","volume":"11","author":"Goodchild","year":"1999","journal-title":"Eur J Neurosci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00011\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T02:51:29Z","timestamp":1568775089000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00011\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,30]]},"references-count":103,"URL":"https:\/\/doi.org\/10.3389\/fneur.2017.00011","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,30]]}}}